3,235 drug assets, with the trial evidence graded and the reasoning shown
Each graded trial is scored on design, size, endpoint and blinding against a published rubric. Pipelines, readouts and financials come from ClinicalTrials.gov, SEC filings and company releases.
- drug assets
- 3,235
- companies
- 1,457
- registry studies
- 87,277
- graded trials
- 3,474
Next Phase 3 readouts
Full calendar →- Nov 2026upadacitinibAtopic Dermatitis · AbbVie
- Nov 2026AbataceptRheumatoid Arthritis · Bristol-Myers Squibb
- Nov 2026retatrutideObesity · Eli Lilly
- Nov 2026metforminSteinert's Disease, Myotonic Dystrophy 1, Metformin
- Nov 2026ObicetrapibAtherosclerotic Cardiovascular Disease · A. Menarini
- Nov 2026TadalafilFontan Palliation · Eli Lilly
Estimated primary-completion dates from ClinicalTrials.gov. They move.
Latest changes
All changes →- 20 NovAbivax Statement on Short Seller ReportAbivax
- 20 NovAvenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private PlacementAvenzo Therapeutics, Inc.
- 20 NovTeva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare ConferenceTeva Pharmaceutical Industries
- 20 NovAvalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)Avalo Therapeutics, Inc.
- 20 NovTrial status changed: Psilocybin (COMP360)Not yet recruiting → Suspended
- 20 NovPrimary readout date moved: BI 30002022027-02-21 → 2026-10-11
Evidence outlook · lead readout
ABTECT - Maintenance (NCT05535946) · Ulcerative Colitis
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
ABTECT - Maintenance (NCT05535946): This trial randomized responder patients to obefazimod 25 mg, 50 mg, or placebo under triple-blind conditions, with a large sample size (over 1,100 participants enrolled across the program), and its primary endpoint was clinical remission, a hard, disease-defining measure of ulcerative colitis activity. The comparison clearly favored obefazimod over placebo with a large effect size and high statistical significance, meeting all the elements needed for strong evidence: real randomization, blinding, an adequately sized placebo control, a hard clinical endpoint, and a statistically significant favorable result.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Crohn's Disease · Phase 2
Featured trials
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ABTECT-1 NCT05507203 · Ulcerative Colitis The trial was randomized, blinded, and placebo-controlled with a hard clinical/endoscopic primary endpoint (clinical remission), and both the 25 mg and 50 mg doses produced significantly higher remission rates than placebo (23.8% and 21.7% vs 2.5%, both P<0.0001). Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05507203 | 3 | Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8 (8 weeks) 2025-06-24 | ABTECT-1 (NCT05507203), clinical remission at Week 8: placebo 2.5% (4/158), 25 mg 23.8% (38/160, p<0.0001), 50 mg 21.7% (69/318, p<0.0001; placebo-adjusted +19.3%) | Reliable signal | link ↗ |
View 2 more trials
ABTECT-2 NCT05507216 · Ulcerative Colitis The trial was randomized, blinded, and placebo-controlled with a hard clinical/endoscopic primary endpoint, but the result was mixed: the 50 mg dose significantly beat placebo (19.8% vs 6.3%, P=0.0001) while the 25 mg dose did not (11.3% vs 6.3%, P=0.1034), so the trial did not cleanly confirm a benefit across doses. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05507216 | 3 | Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8 (8 weeks) 2025-06-24 | ABTECT-2 (NCT05507216), clinical remission at Week 8: placebo 6.3% (10/159), 25 mg 11.3% (18/159, p=0.1034, not significant), 50 mg 19.8% (63/318, p=0.0001; placebo-adjusted +13.4%) | Partial signal | link ↗ |
ABTECT - Maintenance NCT05535946 · Ulcerative Colitis This trial randomized responder patients to obefazimod 25 mg, 50 mg, or placebo under triple-blind conditions, with a large sample size (over 1,100 participants enrolled across the program), and its primary endpoint was clinical remission, a hard, disease-defining measure of ulcerative colitis activity. The comparison clearly favored obefazimod over placebo with a large effect size and high statistical significance, meeting all the elements needed for strong evidence: real randomization, blinding, an adequately sized placebo control, a hard clinical endpoint, and a statistically significant favorable result. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05535946 | 3 | Rate of subjects in clinical remission at Week 44; Number and percentage of all treatment-emergent adverse events (TEAEs) (Week 44); Number and percentage of all serious adverse events (SAEs) (Week 44); Number and percentage of all causally related TEAEs/SAEs (Week 44) 2026-04-28 | ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001 | Reliable signal | link ↗ |
- Trial designThe signal grades the trial's design, size, endpoint and blinding.
- The reasoning is shownEvery graded trial carries its rationale.
- How the outlook works →
Tools
- Asset rosterFilter every asset by indication, mechanism, stage and company.
- Readout calendarRegistry primary-completion dates for every tracked trial.
- Share-price chartsCompare companies' prices with trial and filing events marked.
- MechanismsEvery target, with the drugs that act on it and their stages.
- Ask AIQuestions answered from the database, with each claim cited.
Browse by therapeutic area
Educational research only, not investment advice. Evidence quality is graded; securities never are.